Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamerbio

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

GOSS

Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib&#39;s clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets.

Gossamer Bio&#39;s Clean Safety Profile Differentiates It From Merck, Analyst Says

penny stocks tips 1

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

PFHO

Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying

movers image

Intraday Update

AAGR

ADTN

ALUR

APLD

AREB

ASAN

BNAI

CABA

CDMO

CIFR

CLOV

CRKN

DMTK

IPDN

KAVL

KRKR

MBIO

MINM

MOLN

ORGS

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RELI

SHCR

SMTK

SPEC

SRPT

SWBI

TPHS

TREX

WAVE

ZCAR

Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Gossamer Bio Inc

GOSSAN RESOURCES LTD CDA by Gossan Resources Ltd.

Gossan Resources Ltd

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 20 years by 4.04% on an annualized basis producing an average annual return of 12.25%. Currently, UnitedHealth Group has a market capitalization of $429.85 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 20 years ago, it would be worth $10,265.82 today based on a price of $467.08 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740525310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) has outperformed the market over the past 15 years by 6.56% on an annualized basis producing an average annual return of 18.31%. Currently, Advanced Micro Devices has a market capitalization of $169.05 billion. 
Buying $1000 In AMD: If an investor had bought $1000 of AMD stock 15 years ago, it would be worth $12,405.73 today based on a price of $104.17 for AMD at the time of writing.
<h3>Advanced Micro Devices's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740524410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Advanced Micro Devices 15 Years Ago Would Be Worth Today

ZoomInfo Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares are trading higher in Tuesday&#8217;s after-hours session on the heels of the company&#8217;s fourth-quarter results. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/b43956498/zoominfo-announces-fourth-quarter-and-full-year-2024-financial-results">of the report</a>.
<ul>
<li>Q4 Revenue: $309.1 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $297.63 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 26 cents, versus estimates of 22 cents</li>
</ul>
Total revenue was down 2% year-over-year. ZoomInfo generated $109 million in cash flow from operations and $93.6 million in unlevered free cash flow during the quarter. The company ended the quarter with $139.9 million in cash and cash equivalents. 
&#8220;Our AI innovation and commitment to customer success helped us improve financial performance faster than expected, with strength continuing into 2025. With our operational improvements taking hold, we are delivering better-than-expected revenue, profitability, and free cash flow,&#8221; said Henry Schuck, founder and CEO of ZoomInfo. 
ZoomInfo repurchased $562.3 million of its common stock in 2024 and ended the year with $137.6 million remaining under the repurchase program. The company&#8217;s board approved an additional $500 million buyback authorization in February.
ZoomInfo also announced that it added Rob Giglio&nbsp;to its board, effective March 1. Patrick McCarter has resigned from his role on the board, effective Feb. 28. 
See Also: <a href="https://www.benzinga.com/general/entertainment/25/02/43958798/amc-q4-earnings-revenue-beat-eps-in-line-attendance-up-20-shares-climb">AMC Q4 Earnings: Revenue Beat, EPS In Line, Attendance Up 20%, Shares Climb</a>
Outlook: ZoomInfo expects first-quarter revenue to be in the range of $294 million to $297 million versus estimates of $292.41 million. The company sees first-quarter adjusted earnings of 22 cents to 23 cents per share versus estimates of 22 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
ZoomInfo expects full-year 2025 revenue to be between $1.185 billion and $1.205 billion. The company anticipates full-year adjusted earnings of 95 cents to 97 cents per share. 
ZI Price Action: <a href="http://benzinga.com/quote/zi">ZoomInfo shares</a> were up 18.05% after-hours, trading at $11.25 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of ZoomInfo.

Earnings

Guidance

Management

After-Hours Center

ZoomInfo Technologies Q4 Earnings: Revenue Beat, EPS Beat, Strong Guidance, Shares Surge

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 20 years by 1.99% on an annualized basis producing an average annual return of 10.2%. Currently, Chubb has a market capitalization of $111.18 billion. 
Buying $100 In CB: If an investor had bought $100 of CB stock 20 years ago, it would be worth $703.12 today based on a price of $277.45 for CB at the time of writing.
<h3>Chubb's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740523517_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Barrington Research analyst Alexander Paris maintains Interface (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) with a Outperform and maintains $30 price target.

Price Target

TILE

Barrington Research Maintains Outperform on Interface, Maintains $30 Price Target

Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are surging in Tuesday&#8217;s after-hours session after the company filed its delayed quarterly and annual reports with the <a href="https://www.benzinga.com/news/25/02/43955247/super-micro-computer-smci-stock-is-down-9-whats-going-on">U.S. Securities and Exchange Commission</a>.
What Happened: After the market close on Tuesday, Super Micro filed its delayed annual report for the fiscal year ended June 30, 2024, as well as its delayed quarterly reports for the three-month periods ended Sept. 30, 2024 and Dec. 31, 2024.
Super Micro's independent auditor Ernst &amp; Young&nbsp;resigned last October over&nbsp;governance and transparency concerns, which caused the company to delay the filing of its quarterly and full-year results. Following the resignation, an independent Special Committee found no evidence of fraud or misconduct on the part of management or the company&#8217;s board.
&#8220;We disagreed with EY's decision to resign as our independent registered public accounting firm for a number of reasons &#8230; Due to EY's stated concerns and subsequent resignation, we were unable to timely file our Annual Report on Form 10-K,&#8221; the company said in an explanatory note in Tuesday&#8217;s filing.
See Also:<a href="https://www.benzinga.com/trading-ideas/movers/25/02/43959030/intel-corporation-shares-are-down-today-whats-going-on"> Intel Corporation Shares Are Down Today: What&#8217;s Going On?</a>
Super Micro reported <a href="https://www.benzinga.com/news/earnings/25/02/43641646/super-micro-reports-preliminary-q2-earnings-company-expects-file-delayed-reports-coming-weeks">preliminary second-quarter financial results</a> earlier this month. The company said at the time it expected to report second-quarter revenue of $5.6 billion to $5.7 billion and adjusted earnings of 58 cents to 60 cents per share.
The audited results filed on Tuesday show Super Micro brought in $5.68 billion in revenue in the second quarter. The company reported second-quarter earnings of 54 cents per share, below the lower end of the guidance range Super Micro provided two weeks ago. 
Despite the apparent earnings miss, shares are soaring in extended trading after the company met the deadline for filing its delayed reports, which was set to expire on Tuesday. 
SMCI Price Action: <a href="http://benzinga.com/quote/smci">Super Micro shares</a> were up 22.38% after hours, trading at $55.75 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Tech

SMCI

Super Micro Computer Stock Is Soaring After Hours: What's Going On?

Jones Trading analyst Jason Weaver maintains CTO Realty Growth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTO#NYSE">CTO</a>) with a Buy and maintains $22 price target.

Jones Trading Maintains Buy on CTO Realty Growth, Maintains $22 Price Target

Bernstein analyst Robin Zhu upgrades Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) from Market Perform to Outperform and raises the price target from $104 to $165.

Upgrades

BABA

Bernstein Upgrades Alibaba Gr Hldgs to Outperform, Raises Price Target to $165

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 8.74% on an annualized basis producing an average annual return of 19.64%. Currently, Boston Scientific has a market capitalization of $148.32 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $5,903.87 today based on a price of $100.50 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740522627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today

Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) reported quarterly earnings of $0.12 per share. This is a 50 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $17.30 million. This is a 4.16 percent decrease from sales of $18.05 million same period last year.

Earnings Beats

Earnings Misses

SLNG

Stabilis Solutions Q4 EPS $0.12, increase over earnings of $0.08 during last year same period. Sales $17.30M decreased from sales of $18.05 during last year same period.

WIIM

SCCO

Shares of copper stocks are trading higher after President Trump reportedly ordered a new tariff probe into US copper imports.

Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) reported its fourth-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/n43956202/axon-2024-revenue-grows-33-to-2-1-billion-third-consecutive-year-of-30-annual-growth">details from the report. </a>
The Details: Axon Enterprise reported quarterly earnings of $2.08 per share, which beat the analyst consensus estimate of $1.40. Quarterly revenue clocked in at $575 million, which beat the analyst consensus estimate of $566.08 million and is an increase over revenue of $432.14 million from the same period last year.
For fiscal 2024 Axon reported: 
<ul>
<li>Axon Cloud &amp; Services revenue grew 44% to $806 million</li>
<li>Annual recurring revenue grew 37% to $1 billion</li>
<li>Annual net income of $377 million supported non-GAAP net income of $466 million</li>
</ul>
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43949800/tesla-competes-against-chinese-rivals-with-one-hand-tied-behind-its-back-analyst"> Tesla Competes Against Chinese Rivals &#8216;With One Hand Tied Behind Its Back&#8217;: Analyst</a>
&#8220;We closed 2024 with record quarterly revenue of $575 million in Q4, up 34% year over year, for our 12th consecutive quarter of 25%+ growth. TASER revenue of $221 million grew 37% year over year, fueled by the continued scaling of TASER 10 and growing adoption of our VR training solutions,&#8221; the company wrote in a letter to shareholders. 
&#8220;Sensors &amp; Other revenue of $124 million grew 18% year over year, supported by continued strong demand for Axon Body 4 and Axon Fleet 3. Axon Cloud &amp; Services accounted for 40% of our total revenue, growing 41% year over year to $230 million as adoption of our premium subscription offerings continued to build,&#8221; the company said. 
Outlook: Axon Enterprise sees fiscal 2025 revenue in a range of $2.55 billion to $2.65 billion, versus the $2.55 billion estimate. 
AXON Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Axon Enterprise shares are up 12.75% after hours at $559.99 Tuesday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43951080/bitcoin-plunges-as-consumer-confidence-falls-whats-driving-markets-tuesday">Bitcoin Plunges As Consumer Confidence Falls: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image courtesy of Axon Enterprise, Inc.

AXON

Axon Enterprise Shares Rally After Better-Than-Expected Q4 Results, Strong Forward Guidance

<a href="https://www.reuters.com/world/us/trump-orders-new-tariff-probe-into-us-copper-imports-2025-02-25/" title="https://www.reuters.com/world/us/trump-orders-new-tariff-probe-into-us-copper-imports-2025-02-25/">https://www.reuters.com/world/us/trump-orders-new-tariff-probe-into-us-copper-imports-2025-02-25/</a>

Macro Economic Events

Economics

'Trump Orders New Tariff Probe Into U.S. Copper Imports; U.S. Commerce Secretary Lutnick Says Will Investigate Possible Imposition Of Tariffs To Rebuild U.S. Copper Industry, Says "No Exemptions, No Exceptions; It's Time For Copper To Come Home"; White House Official Says President Trump Will Recognize Copper Sector As National Security Issue, Commerce Dept Will Investigate Under Section 232' - Reuters News

Super Micro Computer shares are trading higher after the company filed its quarterly report.

Effective February 19, 2025, Stephanie F. Pope no longer held the title of Chief Operating Officer of The Boeing Company (the "Company"). Ms. Pope continues to serve as Executive Vice President; President and Chief Executive Officer, Boeing Commercial Airplanes.On February 19, 2025, Sabrina Soussan and the Board of Directors of the Company decided that Ms. Soussan would not stand for re-election at the Company's 2025 Annual Meeting of Shareholders. The decision was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. In connection with this decision, the Board approved a reduction in its size, effective as of the 2025 Annual Meeting of Shareholders.

Boeing's Stephanie Pope Steps Down As COO, Continues As EVP And CEO Of Commercial Airplanes; Sabrina Soussan To Exit Board In 2025, Board Size To Reduce

Super Micro Computer Q2 2025 Revenue $5.678B Vs $3.665B YoY

Super Micro Computer Q2 2025 Diluted EPS $0.51 Vs $0.51 YoY

Super Micro Computer Q2 2025 EPS $0.54 Vs $0.55 YoY

Luxfer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXFR#NYSE">LXFR</a>) is looking for FY2025 Adj EPS of $0.95-$1.05 vs $1.05 analyst estimate..

LXFR

Luxfer Holdings Sees FY2025 Adj EPS $0.95-$1.05 vs $1.05 Est

Luxfer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXFR#NYSE">LXFR</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.22 by 31.82 percent. This is a 222.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $103.40 million which beat the analyst consensus estimate of $89.50 million by 15.53 percent. This is a 7.82 percent increase over sales of $95.90 million the same period last year.

Luxfer Holdings Q4 Adj $0.29 Beats $0.22 Estimate, Sales $103.40M Beat $89.50M Estimate

Press Releases

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Comments

Gossamer Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga